The cash cushion is also very solid. Genmab A/S is a high-margin, royalty-focused biotechnology company with strong partnerships with J&J, AbbVie, and Pfizer. Darzalex is the company’s main revenue driver and has patent protection to sustain growth for at least four more years. The company has a solid balance sheet, low P/E and PEG ratios, high free cash flow yield, and active share buyback programs. Genmab is a Denmark-based company focused on developing innovative antibody therapies, headquartered in Copenhagen. CEO Jan van de Winkel made significant organizational changes to rescue the company from a financial crisis. By selling its manufacturing facility and shifting to a royalty-based model, the company achieved roughly a 95% profit margin. Products like Tivdak and Epkinly, developed jointly with Pfizer and AbbVie, are approved therapies. DuoBody technology, which produces bispecific antibodies, plays a key role in Genmab’s growth. Genmab has a broad product pipeline and increasing R&D investments. so lagged this much is meaningless
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
$GMAB
The cash cushion is also very solid. Genmab A/S is a high-margin, royalty-focused biotechnology company with strong partnerships with J&J, AbbVie, and Pfizer. Darzalex is the company’s main revenue driver and has patent protection to sustain growth for at least four more years. The company has a solid balance sheet, low P/E and PEG ratios, high free cash flow yield, and active share buyback programs. Genmab is a Denmark-based company focused on developing innovative antibody therapies, headquartered in Copenhagen. CEO Jan van de Winkel made significant organizational changes to rescue the company from a financial crisis. By selling its manufacturing facility and shifting to a royalty-based model, the company achieved roughly a 95% profit margin. Products like Tivdak and Epkinly, developed jointly with Pfizer and AbbVie, are approved therapies. DuoBody technology, which produces bispecific antibodies, plays a key role in Genmab’s growth. Genmab has a broad product pipeline and increasing R&D investments. so lagged this much is meaningless